How do you decide on the type of ovarian suppression (GnRH agonist vs. GnRH antagonist) in premenopausal patients treated with an AI?

Based on current available literature in Breast Cancer it is premature to change to GnRH antagonist such as Degarelix. While action of onset is more rapid with Degarelix (3 days) versus triptorelin (14days) (GnRH agonist) side effects are more pronounced and efficacy data is still lacking.

In the re...